WHIM Syndrome Market Outlook, Trends And Future Opportunities (2024-2031)

WHIM Syndrome Market Outlook, Trends And Future Opportunities (2024-2031)

WHIM Syndrome Market, By Product Type (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Others), By Application (Hypogammaglobulinemia, Neutropenia, Human Papillomavirus Infections, Others), By End-User (Hospitals, Clinics, Others), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Mar 2024
  • Author(s): Sagar Karlekar
  • Report ID: IDA64
  • Region: Global
  • Format: PDF/EXCEL

Table Of Contents:

Chapter 1. Research Methodology and Scope

  • Market Segmentation and Scope
  • Regional Coverage
  • Objectives

Chapter 2. Executive Summary

  • Market Landscape
  • Market Size & Forecast
  • Competitive Landscape

Chapter 3. WHIM Syndrome Market: By Product Type

  • By Product Type Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • Launch of subcutaneous immunoglobulin therapies
    • Rising adoption of monoclonal antibody treatments
  • Advancements in gene therapy Market Restraints
    • High costs of novel therapies
    • Low awareness among physicians

Chapter 4. WHIM Syndrome Market: By Application

  • By Application Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • Increasing prevalence of hypogammaglobulinemia
    • Rising cases of chronic lung diseases
  • Growth in immunodeficiency disorders Market Restraints
    • Delayed diagnosis due to nonspecific symptoms
    • Treatment challenges due to disease heterogeneity

Chapter 5. WHIM Syndrome Market: By End-User

  • By End-User Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • Improving healthcare infrastructure in emerging markets
    • Favorable reimbursement policies
  • Increasing insurance coverage Market Restraints
    • High treatment costs at hospitals
    • Limited expertise at small clinics

Chapter 6. WHIM Syndrome Market: Regional Market Trends, Size, and Future Outlook

  • North America Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • High PID incidence and diagnosis rates
    • Presence of key players
  • Favorable reimbursement policies Market Restraints
    • Premium pricing of novel therapies Competitive Outlook
  • Europe Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • High PID incidence and diagnosis rates
    • Presence of key players
  • Favorable reimbursement policies Market Restraints
    • Premium pricing of novel therapies Competitive Outlook
  • APAC Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • High PID incidence and diagnosis rates
    • Presence of key players
  • Favorable reimbursement policies Market Restraints
    • Premium pricing of novel therapies Competitive Outlook
  • RoW Market Size, CAGR, and Forecast 2023-2031 Technology Landscape Market Drivers
    • High PID incidence and diagnosis rates
    • Presence of key players
  • Favorable reimbursement policies Market Restraints
    • Premium pricing of novel therapies Competitive Outlook

Chapter 7. WHIM Syndrome Market: Competitive Landscape

  • Takeda
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • CSL Behring
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Grifols
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Octapharma
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • ADMA Biologics
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Bio Products Laboratory
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • China Biologic Products
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Biotest AG
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Kedrion Biopharma
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • LFB Group
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Emergent BioSolutions
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Baxter International
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Sanquin Plasma Products
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Mitsubishi Tanabe Pharma Corporation
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Thermo Fisher Scientific
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • PerkinElmer Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Danaher Corporation
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Research Methodology
    • Primary Research
    • Secondary Research
    • Assumptions
    • IDataAcumen Analysis
    • Paid Databases
  • Appendix
    • About Us

Frequently Asked Questions

US$ 340 million in 2023

Small patient pool, High treatment costs, Lack of curative therapies

Intravenous immunoglobulin replacement therapies

Takeda, CSL Behring, Grifols, Octapharma, ADMA Biologics

CAGR of 4.2%, Market size of USD 472.5 million in 2031